VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | The role of venetoclax in previously treated Waldenström’s macroglobulinemia

In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights the important role of venetoclax for patients with previously treated Waldenström’s macroglobulinemia (WM), and shares his excitement for other BCL2 inhibitors being explored in the field. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter